Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cox-Regression analysis showed a significant and independent influence of TP53 mutation on tumour progression in comparison with tumour grade, stage and history of prior bladder cancer.
|
18425359 |
2008 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the FGFR3 and TP53 genes have been shown to define two distinct pathways in superficial papillary and invasive UCC disease, respectively.
|
15347601 |
2005 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results are consistent with the literature in that mutations in p53 are predominantly found in high grade bladder cancer (Odds Ratio = 4.05, Fisher Exact P = 0.104); however, the results were not statistically significant due to small numbers.
|
7957118 |
1994 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the presence of the p53 gene mutation may provide important clues to the factors involved in bladder cancer.
|
7715016 |
1995 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mutation profiles of p53 and K-ras genes in pancreatic cancer resemble that in bladder cancer rather than that in lung cancer.
|
11561602 |
2002 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants in p53 codon 72 increased the risk of bladder cancer among smokers.
|
15764300 |
2005 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that both the unique DNA binding specificity of 4-ABP and cytosine methylation contribute to the mutational spectrum of the p53 gene in human bladder cancer.
|
12009904 |
2002 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 - molecular soldier's mutations in bladder cancer in the Kashmiri population.
|
21517233 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians.
|
20630574 |
2010 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of the comet-FISH assay to demonstrate repair of the TP53 gene region in two human bladder carcinoma cell lines.
|
12492368 |
2003 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Various human p53 mutants (V143A, V173L, H179Q, N247I and R273H) were introduced to the TCC-SUP bladder carcinoma cell line to establish stable transfectants.
|
11435891 |
2001 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There appeared to be no consistent mutation sites in exons 4 to 11 of the p53 gene and no specific patterns of the mutation in bladder cancer.
|
1540947 |
1992 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
|
23356517 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice.
|
9473773 |
1998 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
|
8558845 |
1995 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that altered repair and detoxification due to genetic polymorphism may influence the occurrence of p53 mutations in bladder cancer.
|
16343742 |
2006 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The minor allele (Trp/Gln) carriers of the p53 codon 248 demonstrated a 1.7-fold risk for BC.
|
22101376 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, on individual SNP analysis only individuals with the p53 intron 3 16-bp duplication polymorphism variant allele had a significantly reduced bladder cancer risk (odds ratio [OR] = 0.74, 95% confidence interval [CI], 0.56-0.96).
|
18361427 |
2008 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer.
|
19523860 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The alterations of the P53 gene were considered to correlate with tumor grade, and contribute to the malignant progression of bladder cancer.
|
9179671 |
1997 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of bladder cancer by analysis of the allelic loss of the p53 gene in urine samples using blunt-end single-strand conformation polymorphism.
|
9291429 |
1997 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in p53 and pRb, products of the chromosomes 17p13 TP53 and 13q14 RB tumor suppressor genes, occur in approximately 50% and approximately 33% of bladder cancers respectively, and are associated with later stage, higher grade disease. p53 and pRb alterations are also known to occur in early stage bladder carcinoma in situ where they are thought to represent a poor prognosis for tumor progression.
|
8893868 |
1996 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TP53 codon72 polymorphism appears to play a crucial role in determining the association between TP53 haplotype and the incidence and prognosis of bladder cancer.
|
22178231 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of mutations in exons 5-8 of the P53 gene in patients with bladder cancer was lower (3.3% in grade G1, 24% in G2, and 39% in G3) than the data reported in the literature.
|
17495352 |
2007 |